SOPHiA GENETICS™ is excited to be a part of the Healthcare Information and Management Systems Society annual meeting, held in person in Chicago, IL, from April 17th-21th.
You will have the chance to chat with our experts at booth #3859 and demo the universal SOPHiA DDM™ Platform.
Harnessing multimodal data analytics to guide clinical decisions
Lunch & Learn
Thursday, April 20
11am - 12:15 pm
Room W470B
Fragmented, missing, and unstructured data stand in the way of realizing the potential of multimodal data analytics to optimize precision medicine. This talk tackles these obstacles, from identifying vital patient and treatment response data to breaking down data silos and fostering integration. Using a machine learning-powered approach, we will show how one can standardize multimodal information to drive accurate insights and guide decision-making in healthcare. Leveraging on the Azure Cloud infrastructure and capabilities, the SOPHiA DDM™ Platform enables multimodal data visualization (longitudinal view of data modalities across the care journey) and cohorting (contextualizing the patient within one of the largest networks of global institutions) to ultimately generate comprehensive insights. Secure and compliant, the platform is being tested across sites in the US and Europe in the context of ongoing clinical trials such as DEEP-Lung-IV (NCT04994795) and UroCCR 15 (NCT05404685).
Presented by:
Abhi Verma, MBA - SVP and Chief Technology Officer, SOPHiA GENETICS
Dr. David Rhew, MD - Global Chief Medical Officer & VP of Healthcare, Microsoft
Jeff Gaudet, Ph.D - Medical Science Liason, SOPHiA GENETICS
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.